Form 4: Vir Bio CEO's Equity Update: RSU Vesting & Option Grant

Vir Biotechnology CEO Marianne De Backer reported the acquisition of restricted stock units and stock options, alongside a mandatory sale of shares for tax obligations.

Summary

• Marianne De Backer, CEO and Director of Vir Biotechnology, Inc. (VIR), reported changes in her beneficial ownership.
• Acquired 285,000 shares of common stock on February 22, 2026, through the vesting of restricted stock units (RSUs) under the Issuer's Equity Incentive Plan.
• Disposed of 19,039 shares of common stock on February 23, 2026, at a price of $7.4528 per share. This sale was automatic and mandatory under a Rule 10b5-1 plan to satisfy tax withholding obligations related to the RSU vesting.
• Acquired 570,000 stock options on February 22, 2026, with an exercise price of $7.56 per share and an expiration date of February 21, 2036.
• The stock options will vest 25% on February 22, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
• Following these transactions, De Backer directly owns 1,035,466 shares of common stock and 570,000 stock options.
• An additional 53,118 shares are indirectly held through the Ureel-De Backer Family Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and tax-related transactions rather than a significant shift in company fundamentals or insider sentiment.

Positives

• Acquisition of 285,000 shares of common stock via RSU vesting, increasing direct equity stake.
• Grant of 570,000 stock options, providing long-term incentive and potential future equity upside.

Negatives

• Disposal of 19,039 shares of common stock, reducing direct beneficial ownership, even if for tax purposes.

Future Outlook

The acquired stock options will vest over time, with 25% becoming exercisable on February 22, 2027, and the remainder vesting in 36 equal monthly installments thereafter, indicating a long-term incentive structure for the CEO.

Management Comments

• The sale of 19,039 shares represents an automatic and mandatory sale under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs.
• The sale does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options, along with subsequent tax-related sales, are standard practices for executive compensation in the biotechnology industry, aligning management's interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• 53,118 shares are indirectly held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.

Stakeholder Impact

• Shareholders: The CEO's increased equity stake through RSU and option grants aligns her interests with long-term shareholder value, while the tax-related sale is a routine, non-discretionary event.
• Employees: The equity incentive plan provides a framework for executive compensation, which can influence broader employee incentive structures.

Next Steps

• Continued vesting of 25% of stock options on February 22, 2027.
• Subsequent monthly vesting of the remaining stock options over 36 months.

Key Dates

Recommendation

This Form 4 details routine executive compensation, including RSU vesting and stock option grants, alongside a mandatory tax-related share sale. These transactions do not reflect discretionary trading based on new material information and therefore do not warrant a change in investment recommendation.

Keywords

Vir Biotechnology, VIR, Form 4, Insider Transaction, CEO, Restricted Stock Units, RSU, Stock Options, Equity Incentive Plan, Rule 10b5-1, Executive Compensation